Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...

An experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breast cancer, ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectableCompany ...

Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs. Key operational highlights included a recent FDA meeting to discuss the potential for ...

the potential therapeutic benefit of mavorixafor; the initiation, timing, progress, and results of our current and future preclinical studies and clinical trials, including the completed Phase 2 ...

Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, there will be a question and ...

In the world of nuclear medicine, health care professionals face the challenge of safeguarding themselves and their patients ...

“I am very encouraged by the progress of our gene therapy programs and the clinical and regulatory milestones achieved ... which are subject to risks and uncertainties. We may, in some cases, use ...

In the first half of 2025, Werewolf expects to provide an update on the WTX-124 clinical development program, including data ...

Recent Progress and Upcoming Late-Stage Pipeline Milestones The Company remains focused ... safety and immunogenicity. Propionic acidemia (PA) therapeutic: In an ongoing Phase 1/2 study designed to ...